Loss of cardiomyocyte eukaryotic elongation factor 1A2 in mice triggers cardiomyopathy due to defective proteostasis

This study demonstrates that the loss of cardiomyocyte-specific eEF1A2 triggers cardiomyopathy by impairing protein folding and autophagy, leading to proteostasis failure that can be rescued by mTORC1 inhibition.

The Gist

The Big Picture: The Heart's "Quality Control" Manager

Imagine your heart is a massive, high-speed factory that never stops running. Its job is to pump blood, but to do that, it needs to constantly build and repair millions of tiny machines (proteins) that make up the heart muscle.

In this factory, there are two main managers who help build these machines: Manager 1 (eEF1A1) and Manager 2 (eEF1A2).

• Manager 1 works everywhere in the body (in the liver, skin, brain, etc.).
• Manager 2 is a specialist. He only works in the adult heart, the brain, and the muscles used for movement.

Scientists already knew that if you lose Manager 2 in a baby, the heart fails. But they didn't know what happened if an adult lost him. This study asked: What happens if we fire Manager 2 from an adult heart?

The Experiment: Firing the Specialist

The researchers created a special group of mice where they could "fire" Manager 2 (eEF1A2) from the adult heart cells at will.

The Result:
Within two months, the hearts of these mice started to fail. They became weak, enlarged (like a stretched-out balloon), and filled with scar tissue. The mice started dying.

The Surprise:
Usually, when you fire a manager responsible for building things, the factory slows down. But here, the factory kept building at the same speed! The heart cells were still making proteins just fine. So, why did the heart fail?

The Real Problem: The "Trash" Pile

The scientists discovered that Manager 2 wasn't just a builder; he was also a Quality Control Inspector and a Janitor.

1. The Folding Problem: Imagine the factory is making complex origami cranes. Manager 2 helps fold the paper correctly as it comes off the assembly line. Without him, the cranes come out crumpled and misshapen. In the heart, these "crumpled cranes" are misfolded proteins. They pile up and clump together, forming toxic garbage.
2. The Trash Collection Failure: Normally, the heart has a trash collection system called autophagy (literally "self-eating") that sweeps up this garbage and recycles it.
   • In the mice without Manager 2, the trash trucks (autophagosomes) were showing up, but they were getting stuck. They couldn't dump their load into the recycling bin (the lysosome).
   • The result? A massive pileup of toxic protein garbage inside the heart cells. This garbage clogged the machinery, causing the heart to stop working.

The "Double Knockout" Twist

The researchers wondered: "If we fire Manager 2, does Manager 1 step in to save the day?"

• Answer: Yes, but only partially. When Manager 2 was fired, Manager 1 worked harder to compensate. This kept the heart alive for a while, but the "garbage pile" still grew, leading to heart failure eventually.
• The Ultimate Test: When they fired both managers, the mice died very quickly (within 6 weeks) in a sudden manner. This proved that Manager 1 is essential for keeping the heart running, but Manager 2 is the one specifically needed to keep the "garbage" clean.

The Solution: The "Reset Button" (Rapamycin)

The scientists found a clue: The heart cells were stuck in a "stop cleaning" mode because a master switch called mTORC1 was stuck in the "ON" position. This switch tells the cell to build new things but stops it from cleaning up old trash.

They treated the sick mice with a drug called Rapamycin, which acts like a reset button for this switch.

• What happened? Rapamycin turned the "cleaning mode" back on.
• The Result: The heart cells finally swept up the toxic protein garbage. The heart function improved, the heart stopped getting bigger, and the mice lived much longer.

The Takeaway

This study teaches us three big lessons:

1. It's not just about building: The heart doesn't just need to build proteins; it needs to make sure they are folded correctly and that the trash is taken out.
2. Manager 2 is a Janitor: eEF1A2 (Manager 2) acts as a "chaperone" (a helper) that ensures proteins fold correctly and helps the cell's cleaning crew work.
3. A New Treatment Path: For people with genetic mutations that break this "Manager 2" system (causing heart failure and neurological issues), drugs like Rapamycin might be a way to fix the problem by forcing the heart to clean up its own mess.

In short: The heart failed not because it stopped working, but because it stopped cleaning up its own mistakes. By teaching the heart to clean again, the researchers saved the mice.

Technical Summary

1. Problem Statement

Eukaryotic elongation factor 1A (eEF1A) is essential for delivering aminoacyl-tRNAs to ribosomes during protein synthesis. Mammals express two paralogs: eEF1A1 (ubiquitous) and eEF1A2 (restricted to adult cardiomyocytes, skeletal myocytes, and neurons). While mutations in EEF1A2 are known to cause severe cardiomyopathy, epilepsy, and developmental delay in humans, the underlying molecular mechanisms remain unclear. Previous studies suggested that the cardiomyopathy might be independent of the canonical translation elongation function, as global protein synthesis rates appeared unchanged in some models. The specific role of eEF1A2 in adult cardiac homeostasis and the mechanism by which its loss leads to heart failure were unknown.

2. Methodology

The study employed a multi-disciplinary approach combining genetics, multi-omics, and pharmacological intervention:

• Mouse Models:
  • Eef1a2-cKO: Cardiomyocyte-specific, Tamoxifen-inducible conditional knockout of Eef1a2 in adult mice (6–7 weeks old).
  • Eef1a1/Eef1a2-dKO: Double conditional knockout of both paralogs to assess compensatory mechanisms.
  • Eef1a1-cKO: Control for the dispensability of eEF1A1 in adults.
  • Rapamycin Treatment: Pharmacological inhibition of mTORC1 initiated one month post-deletion to test therapeutic potential.
• Phenotyping:
  • Echocardiography (ejection fraction, chamber dimensions).
  • Histology (Sirius Red for fibrosis, WGA for cardiomyocyte cross-sectional area).
  • Survival analysis (Kaplan-Meier curves).
• Omics & Molecular Analysis:
  • Proteomics & RNA-seq: Performed on whole hearts and isolated cardiomyocytes at 1 month (pre-symptomatic) and 2 months (symptomatic).
  • Ribo-seq (Ribosome Profiling): To measure translational efficiency (TE) and ribosome occupancy.
  • Polysome Profiling: To assess ribosome distribution.
  • Metabolomics: GC-MS analysis of cardiac metabolites.
• Functional Assays:
  • Puromycin Incorporation: To measure global protein synthesis rates.
  • Luciferase Folding/Unfolding Assays: Using Firefly and Renilla luciferase in cardiomyocytes and HEK293 cells to assess protein folding capacity and chaperone activity.
  • Autophagy Markers: Western blot and immunofluorescence for p62, LC3-I/II, Beclin1, Atg7, and LAMP1.
  • Electron Microscopy: To visualize autophagosomes and organelle morphology.

3. Key Contributions & Results

A. Phenotypic Consequences of eEF1A2 Loss

• Cardiomyopathy: Adult-onset deletion of Eef1a2 leads to progressive systolic dysfunction (reduced ejection fraction), cardiac hypertrophy, and fibrosis. Mortality reaches ~45% by 2 months post-deletion.
• Lethality of Double KO: Simultaneous deletion of Eef1a1 and Eef1a2 results in 100% mortality within 6 weeks, occurring suddenly without prior signs of cardiac dysfunction, suggesting eEF1A1 provides a critical, albeit partial, compensatory buffer.
• Global Synthesis: Surprisingly, global protein synthesis (measured by puromycin incorporation) remains unchanged in Eef1a2-cKO hearts, indicating the pathology is not due to a general failure of translation elongation.

B. Mechanistic Insights: Proteostasis and mTORC1

• Post-Transcriptional Upregulation: Despite unchanged mRNA levels, Eef1a2-cKO hearts show a massive upregulation of ribosomal proteins and translation factors (e.g., RPS6, eEF2). Ribo-seq confirms increased translational efficiency (TE) for mRNAs containing 5'-terminal oligopyrimidine (5' TOP) motifs, which are known targets of mTORC1.
• mTORC1 Hyperactivation: Phosphorylation of RPS6 (a marker of mTORC1 activity) is significantly increased in Eef1a2-cKO hearts.
• Defective Autophagy:
  • There is an accumulation of autophagosomes (LC3-II, p62) but a lack of autolysosomes.
  • Immunofluorescence shows p62-positive puncta and protein aggregates (Proteostat-positive) that do not colocalize with the lysosomal marker LAMP1.
  • Electron microscopy confirms a block in autophagic flux (accumulation of autophagosomes, not autolysosomes).
• Protein Folding Defect:
  • Eef1a2-cKO cardiomyocytes exhibit reduced luciferase activity due to misfolding, not reduced transcription or translation.
  • Overexpression of eEF1A2 in HEK293 cells protects against heat-shock-induced unfolding and accelerates refolding.
  • This identifies eEF1A2 as a critical molecular chaperone supporting protein folding in cardiomyocytes.
• Integrated Stress Response (ISR): Loss of eEF1A2 leads to increased phosphorylation of eIF2α, indicating activation of the ISR, yet global translation is maintained due to the compensatory upregulation of ribosomal machinery.

C. Therapeutic Intervention

• Rapamycin Rescue: Early treatment with Rapamycin (mTORC1 inhibitor) initiated one month post-deletion:
  • Normalized survival: Prevented the 45% mortality rate.
  • Restored function: Reversed systolic dysfunction and cardiac hypertrophy.
  • Restored proteostasis: Cleared autophagosomes and protein aggregates by restoring autophagic flux.
  • Limitation: Rapamycin did not reverse established cardiac fibrosis, suggesting fibrosis is a downstream, irreversible consequence or requires a different mechanism.

4. Significance

• Novel Non-Canonical Function: The study establishes that eEF1A2 functions as a co-translational chaperone essential for cardiac proteostasis, independent of its canonical role in translation elongation.
• Mechanism of Cardiomyopathy: It elucidates that EEF1A2 mutations cause heart failure via a proteostasis collapse characterized by mTORC1 hyperactivation, blocked autophagic flux, and accumulation of misfolded proteins.
• Therapeutic Implications: The findings suggest that mTORC1 inhibition (e.g., Rapamycin) is a viable therapeutic strategy for patients with EEF1A2-related cardiomyopathy. This offers a potential treatment avenue for a currently untreatable genetic condition.
• Broader Context: Given that EEF1A2 is also highly expressed in neurons, these findings may provide insights into the pathogenesis of the neurological symptoms (epilepsy, intellectual disability) associated with EEF1A2 mutations, suggesting a shared mechanism of proteostasis failure across tissues.

Conclusion

The paper demonstrates that the loss of eEF1A2 in adult cardiomyocytes triggers a cascade of proteostatic failure driven by mTORC1 hyperactivation and defective autophagy, rather than a simple halt in protein synthesis. The identification of eEF1A2 as a chaperone and the successful rescue of cardiac function via Rapamycin represent a significant breakthrough in understanding and potentially treating EEF1A2-associated cardiomyopathies.